Drug intelligence / Profile preview

FT0024

Development stage: Preclinical
Lead developer: Fovero Therapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

FT0024 is a first-in-class monoclonal antibody targeting Galectin-9 (GAL9), developed by Fovero Therapeutics for the treatment of autoimmune and inflammatory diseases. Galectin-9 is a glycan-binding protein that plays a critical role in immune regulation; FT0024 is designed to reprogram immune responses and restore immune balance in dysregulated states. The program has received non-dilutive funding from Brandon BioCatalyst and the U.S. Department of Defense and is currently in the discovery stage of development.

Targets

LGALS9 (Galectin-9)

Beyond the preview

Go deeper on FT0024.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FT0024.

Explore the full profile